Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evolution of Hypofractionated Stereotactic Irradiation for Radio-Resistant Brain Metastases From D1-3-5 to D1-2-3
Sponsor: Centre Paul Strauss
Summary
The goal of this prospective, multi-center, randomized double-arm clinical trial is to demonstrate a benefit in term of local control of a shorter spread of hypofractionated stereotactic radiotherapy at D1-2-3 vs D1-3-5, in the treatment of "radioresistant" Brain Metastases (BM). This trial aims to recruit patients with 1 to 5 unoperated BM originating from radioresistant primary sites. Patients will be randomly assigned to either the D1-3-5 radiotherapy arm or the D1-2-3 radiotherapy arm. Stereotactic brain irradiation will be administered at a dose of 33 Gy delivered in 3 fractions.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
264
Start Date
2025-10
Completion Date
2030-04
Last Updated
2025-09-11
Healthy Volunteers
No
Conditions
Interventions
D1-3-5 radiotherapy
23.1 Gray (Gy) delivered in 3 fractions of 7.7 Gy at D1, D3, and D5
D1-2-3 radiotherapy
23.1 Gray (Gy) delivered in 3 fractions of 7.7 Gy at D1, D2, and D3
Locations (1)
ICANS
Strasbourg, France